The Library
Diagnosing relapse in children's brain tumors using metabolite profiles
Tools
Tools
Tools
Gill, S. K., Wilson, M., Davies, N. P., MacPherson, L., English, M., Arvanitis, Theodoros N. and Peet, A. C. (2014) Diagnosing relapse in children's brain tumors using metabolite profiles. Neuro-Oncology, Volume 16 (Number 1). pp. 156-164. doi:10.1093/neuonc/not143 ISSN 1522-8517.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1093/neuonc/not143
Abstract
Background: Malignant brain tumors in children generally have a very poor prognosis when they relapse and improvements are required in their management. It can be difficult to accurately diagnose abnormalities detected during tumor surveillance, and new techniques are required to aid this process. This study investigates how metabolite profiles measured noninvasively by 1H magnetic resonance spectroscopy (MRS) at relapse reflect those at diagnosis and may be used in this monitoring process.
Methods: Single-voxel MRS (1.5 T, point-resolved spectroscopy, echo time 30 ms, repetition time 1500 ms was performed on 19 children with grades II–IV brain tumors during routine MRI scans prior to treatment for a suspected brain tumor and at suspected first relapse. MRS was analyzed using TARQUIN software to provide metabolite concentrations. Paired Student's t-tests were performed between metabolite profiles at diagnosis and at first relapse.
Results: There was no significant difference (P > .05) in the level of any metabolite, lipid, or macromolecule from tumors prior to treatment and at first relapse. This was true for the whole group (n = 19), those with a local relapse (n = 12), and those with a distant relapse (n = 7). Lipids at 1.3 ppm were close to significance when comparing the level at diagnosis with that at distant first relapse (P = .07, 6.5 vs 12.9). In 5 cases the MRS indicative of tumor preceded a formal diagnosis of relapse.
Conclusions: Tumor metabolite profiles, measured by MRS, do not change greatly from diagnosis to first relapse, and this can aid the confirmation of the presence of tumor.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Divisions: | Faculty of Science, Engineering and Medicine > Engineering > WMG (Formerly the Warwick Manufacturing Group) | ||||||||
| Journal or Publication Title: | Neuro-Oncology | ||||||||
| Publisher: | OUP | ||||||||
| ISSN: | 1522-8517 | ||||||||
| Official Date: | 2014 | ||||||||
| Dates: |
|
||||||||
| Volume: | Volume 16 | ||||||||
| Number: | Number 1 | ||||||||
| Page Range: | pp. 156-164 | ||||||||
| DOI: | 10.1093/neuonc/not143 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
